Mar De Miguel

Madrid

Staff Writer at BioWorld

Staff Writer at BioWorld Science

Biologist & Science Writer @BioWorld @Clarivate. Contributor @elmundociencia Music lover, cofounder @JungleIndieRock

Featured in: Favicon

bioworld.com Favicon

elmundo.es Favicon

marketscreener.com Favicon

tecnohotelnews.com

Articles

AI-designed DNA allows synthetic control of hematopoiesis

6 days ago | bioworld.com | Mar De Miguel

The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
Lack of NAD does not alter muscle function or accelerate aging

1 week ago | bioworld.com | Mar De Miguel

MusculoskeletalLack of NAD does not alter muscle function or accelerate agingAdult skeletal muscle tolerates a lack of the coenzyme nicotinamide adenine dinucleotide (NAD), according to a study led by scientists at the University of Copenhagen. Their results suggest that adverse effects previously associated with congenital NAD depletion in this tissue may be due to impaired muscle development rather than to a deficiency of this molecule. BioWorld Science Aging Endocrine/metabolic Musculoskeletal
Key genes and educated natural killer cells keep HIV in remission

2 weeks ago | bioworld.com | Mar De Miguel

Home » Key genes and educated natural killer cells keep HIV in remission BioWorld briefs for April 29, 2025. BioWorld MedTech briefs for April 29, 2025. The Trump administrationâ€™s tariff activities provoked another set of responses from both Medtech Europe and the Advanced Medical Technology Association. KRAS mutations are found in more than 90% of pancreatic cancer cases, with the G12D variant being the most prevalent. BioWorld Asia briefs for April 22, 2025
Psychedelics modulate neuroimmune interactions that control fear

2 weeks ago | bioworld.com | Mar De Miguel

Neurology/psychiatricPsychedelics modulate neuroimmune interactions that control fearA research of the neuroimmune mechanisms involved in stress-related fear revealed how astrocytes interact with neurons in the amygdala. The study, led by Harvard scientists, also unveiled that this interaction recruited monocytes to the meninges during chronic stress and showed how psychedelic compounds reversed monocyte accumulation in the meninges and reduced fear behavior.
Germline variants’ impact on pan-cancer proteome

2 weeks ago | bioworld.com | Mar De Miguel

Go ask Alis? New fund aims to rescue biopharma’s trapped cash“They are not zombies, they are fallen angels.” That is view of Nick Johnston, a U.K-based banker who has come up with a new plan to rescue listed companies whose...
PIKfyve enzyme is target to ‘starve’ pancreatic cancer cells

2 weeks ago | bioworld.com | Mar De Miguel

CancerPIKfyve enzyme is target to ‘starve’ pancreatic cancer cellsA metabolic vulnerability of pancreatic ductal adenocarcinoma (PDAC) could be used to address this type of cancer that often resists treatments. Scientists at the University of Michigan have discovered that inhibiting the PIKfyve enzyme prevented tumor development and reduced tumor growth by altering the lipid synthesis these cells rely on.
Commander proteins linked to lysosomal dysfunction in Parkinson’s

3 weeks ago | bioworld.com | Mar De Miguel

Neurology/psychiatricCommander proteins linked to lysosomal dysfunction in Parkinson’sGenes associated with lysosomal dysfunction increase the risk of Parkinson’s disease (PD), according to a study led by scientists at Northwestern University. The discovery also explains why some people who carry a pathogenic variant of the GBA1 gene develop PD or dementia with Lewy bodies (DLB) and others do not. The key lies in the Commander complex, involved in the transport of proteins to this organelle.
Germline variants’ impact on pan-cancer proteome

3 weeks ago | bioworld.com | Mar De Miguel

Makary’s vision for slimmed-down US FDA somewhat reassuringNearly three weeks into the job, U.S. FDA Commissioner Marty Makary provided a comprehensive overview of his vision for the much-reduced agency, even as he’s...
Stem cell therapies show safety in clinical trials in Parkinson's

4 weeks ago | bioworld.com | Mar De Miguel

Stem cell therapies show safety in clinical trials in Parkinson'sStem cell implantation is a step closer to becoming the next strategy against Parkinson's disease. Two clinical trials, one in phase I and the other in phase I/II, have demonstrated their safety and potential to restore dopamine production in the brains of patients with this currently incurable neurodegenerative condition.
Commander proteins linked to lysosomal dysfunction in Parkinson’s

4 weeks ago | bioworld.com | Mar De Miguel

Neurology/psychiatricCommander proteins linked to lysosomal dysfunction in Parkinson’sGenes associated with lysosomal dysfunction increase the risk of Parkinson’s disease (PD), according to a study led by scientists at Northwestern University. The discovery also explains why some people who carry a pathogenic variant of the GBA1 gene develop PD or dementia with Lewy bodies (DLB) and others do not. The key lies in the Commander complex, involved in the transport of proteins to this organelle.